180 Life Sciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2013-01-01
- Employees
- 4
- Market Cap
- $1.8M
- Introduction
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Ma...
Allogene Therapeutics (ALLO) Stock Surges Amid Biotechnology Sector Volatility
Allogene Therapeutics stock rose 5.02% to $2.83, with zero revenue, a $66.36M net loss, and -$0.35 EPS. Despite financial losses, 72% of 18 institutions recommend buying. The biotech sector declined 0.19%, but stocks like Bright Minds Biosciences and Psyence Biomedical gained. Allogene specializes in immuno-oncology, developing allogeneic T-cell products for cancer and autoimmune diseases.
© Copyright 2024. All Rights Reserved by MedPath